focus -WSS

focus

author：explore 2025-08-19 20:44:59 - browse：23

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Trump’s hydroxychloroquine hype: a risk to my treatment and to him

knowledge

WSS

After decades in use, heart stents finally beat placebo

A letter from the executive editor: STAT UnitedHealth investigation

First transplant of an entire human eye performed

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Canadians with cystic fibrosis outlive Americans by a decade

After decades in use, heart stents finally beat placebo

explore

focus

focus

BioMarin wins approval for gene therapy to treat hemophilia A

CVS, Rite Aid closures threaten to worsen pharmacy deserts

United colonoscopy coverage change 'may cost lives,' doctors say

Beware reading your test results before your doctor does

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AstraZeneca lung cancer study comes in below expectations

Bright Health sells Medicare Advantage business to Molina

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Guidelines to prevent youth baseball injuries need more muscle

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

focus

Security flaws in third

Cancer diagnosis changes perspective doctor, former hospital CEO

Ohio still needs to do more to protect the right to abortion

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

A letter from the executive editor: STAT UnitedHealth investigation

First transplant of an entire human eye performed

knowledge

focus

knowledge

entertainment